Severe optic neuritis in a patient with combined neuromyelitis optica spectrum disease and primary Sjögren’s syndrome: a case report
© Tan et al.; licensee BioMed Central Ltd. 2012
Received: 19 June 2012
Accepted: 24 October 2012
Published: 24 November 2012
Optic neuritis, although uncommon, can be the initial presentation of Sjögren’s syndrome. Coexisting Sjögren’s syndrome has also been reported with neuromyelitis optica spectrum disorder. This case report highlights the association between the two diseases and the importance of rheumatological and neurological evaluations in patients with such diagnoses. Distinction of neuromyelitis optica with coexisting connective tissue disease has both prognostic and therapeutic significance for the patient.
We report a case of a 56-year-old Chinese woman who presented with bilateral asymmetric visual loss secondary to optic neuritis. She was subsequently found to be seropositive for neuromyelitis optica immunoglobulin G (NMO-IgG) (anti-aquaporin-4 antibody) and was diagnosed with neuromyelitis optica spectrum disorder. She also fulfilled the international criteria for Sjögren’s syndrome. Despite initial high dose immunosuppressive therapy, she failed to regain vision in one eye.
Patients presenting with optic neuritis and severe visual loss should be screened for neuromyelitis optica and treated appropriately. Neuromyelitis optica has been associated with systemic autoimmune diseases, in particular Sjögren’s syndrome, and current evidence indicates that they are two distinct entities. We recommend that both diagnoses be considered in cases of optic neuritis with severe visual loss.
Optic neuritis (ON), although uncommon, can be the initial presentation of Sjögren’s syndrome (SS). Coexisting SS has also been reported in 2% to 30% of patients with neuromyelitis optica (NMO). NMO is an inflammatory demyelinating disorder of the central nervous system (CNS) characterized by recurrent attacks of ON and longitudinally extensive transverse myelitis (LETM) distinct from multiple sclerosis. The discovery of neuromyelitis optica immunoglobulin G (NMO-IgG) (anti-aquaporin-4 antibody) and its specificity and sensitivity for NMO has led to its incorporation in the diagnostic criteria for NMO. In addition, incomplete forms of NMO (recurrent ON, LETM) and seropositivity for NMO-IgG predicts increased risk of progression to full spectrum NMO, resulting in the designations of these conditions as neuromyelitis optica spectrum disorder (NMOSD). In this article, we present a patient with ON who was found to have both primary SS and NMO-IgG seropositivity, suggestive of NMOSD and review the recent literature concerning the overlap between primary SS and NMOSD.
The patient had sicca symptoms for 12 years and the result of her Schirmer’s test was less than five mm in both eyes; thus fulfilling the international criteria for diagnosis of SS.
A diagnosis of NMOSD and primary SS was made. The patient was started on intravenous methylprednisolone (one mg/kg body weight/day) for five days. As there was no improvement in the vision of the patient’s right eye, plasmapheresis was initiated for the patient on the sixth day. Despite undergoing four cycles of plasma exchange, vision in the patient’s right eye was unchanged and the visual acuity of her left eye was 6/7.5. The right disc showed resolution of disc swelling after three months with subsequent temporal pallor.
This patient’s severe visual loss and degree of intraconal fat stranding was atypical for demyelinating ON or multiple sclerosis. She did not have any atherosclerotic risk factors or elevated levels of erythrocyte sedimentation rate to suggest non-arteritic and arteritic ischemic optic neuropathy respectively. The severe asymmetric bilateral optic neuropathy prompted a search for NMO and associated systemic autoimmune diseases such as SS.
CNS involvement in patients with Sjögren’s syndrome is much less common than peripheral nervous system involvement and ranges from 2% to 25% among patients[4, 5]. Delalande et al. reviewed the neurologic manifestations in 82 patients with Sjögren’s syndrome and found that 13 out of 82 (16%) of patients had visual loss secondary to ON. In another study by Gono et al., three of 17 (18%) primary Sjögren’s syndrome patients had ON.
NMO is characterized by significant morbidity in more than 90% of cases and more than half of the affected patients will be unable to ambulate without assistance and/or be functionally blind by five years.
An association between NMO, NMOSD and systemic autoimmune disease has been reported in the literature. To date, 26 cases of overlap SS and NMO have been identified. Present studies indicate that ON in patients with SS who are seropositive for NMO-IgG signifies the coexistence of two autoimmune diseases rather than a secondary vasculitic complication of the systemic disease. Pittock et al. studied NMO or NMOSD patients who may or may not have overlap SS or systemic lupus erythematosus (SLE) disease and compared them with a control group of SS and/or SLE patients. NMO-IgG was detected only in patients with NMO or NMOSD with or without SS or SLE and was consistently negative in the controls. Jarius et al. also studied serum samples from 109 patients with established or possible systemic autoimmune disease, and vasculitis for the presence of NMO-IgG. They found that NMO-IgG was present only in patients with neurological manifestations consistent with NMO, NMOSD, recurrent ON or LETM. Patients with other neurological manifestations were seronegative. Furthermore, NMO-IgG serum titres in patients with NMOSD and systemic autoimmune disease did not differ significantly from those in a group of unselected control patients with NMOSD but no systemic autoimmune disease. The above studies support the concept of NMO-IgG being involved in the pathogenesis of these neurological diseases and argue against it being part of the polyclonal B cell activation found in systemic autoimmune disease.
There is no current published literature regarding screening for SS in patients with NMO. However, Sánchez-Guerrero et al. assessed the validity of several screening tests (European questionnaire for sicca symptoms, Schirmer’s test, and wafer test) in a group of 336 ambulatory patients with chronic diseases. They found that the combined use of a model consisting of the European questionnaire with at least one affirmative answer, a positive result for Schirmer’s test of less than five mm in five minutes, and positive wafer test results had the best performance in terms of prediction for SS with a likelihood ratio of 9:4. Given the suitability, ease of administration, low cost and minimal discomfort of the tests, they recommended their use in parallel to identify SS in ambulatory patients with chronic diseases. The availability and use of these tests may vary among different institutional practices; however, it is useful to keep in mind these tests when faced with NMO patients with possible SS.
There are therapeutic implications of the diagnosis of NMO and the interrelationships between NMO and/or NMOSD and systemic autoimmune disease. Recognition of the distinct entity of NMO and/or NMOSD from multiple sclerosis (MS) is important because treatment recommended for MS-like ON is not applicable. Patients with NMO-IgG seropositivity have been known to have a high risk of relapse at 50% or greater, and may need maintenance therapy with azathioprine for a minimum of five years. Our patient was advised on long-term immunosuppression with azathioprine; however, she declined treatment due to financial issues. She has remained relapse-free for the past 22 months. It is possible that control of autoimmune disease may be beneficial for the treatment of NMOSD. Although treatment strategies for NMO and/or NMOSD and systemic autoimmune disease are similar and may overlap, care must be taken when treatment involves use of biologic agents targeting tumor necrosis factor and its receptors because there have been reports of associated CNS demyelinating events. Their specific effects on NMO and/or NMOSD are still unknown.
Current literature suggests NMO as a distinct entity from MS requiring different treatment modalities; as such, patients presenting with ON and severe visual loss should be screened for NMO and treated appropriately. Less commonly, ON may be the initial presentation of SS. Rheumatologic evaluation should be undertaken in patients with evidence of clinical and serological autoimmunity. NMO has been associated with systemic autoimmune diseases, in particular SS, and current evidence indicates that they are two distinct entities. Further studies are required to better understand the impact of these systemic diseases and their treatment on the morbidity of NMO and NMOSD.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, Dubucquoi S, Pruvo JP, Vermersch P, Hatron PY: Neurologic manifestations in primary Sjögren’s syndrome. A study of 82 patients. Medicine. 2004, 83: 280-291. 10.1097/01.md.0000141099.53742.16.View ArticlePubMed
- Wingerchuk DM, Weinshenker BG: The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012, 18: 5-10.View ArticlePubMed
- Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG: Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006, 66: 1485-1489. 10.1212/01.wnl.0000216139.44259.74.View ArticlePubMed
- Chai J, Logigian EL: Neurological manifestations of primary Sjögren’s syndrome. Curr Opin Neurol. 2010, 23: 509-513. 10.1097/WCO.0b013e32833de6ab.View ArticlePubMed
- Gono T, Kawaguchi Y, Katsumata Y, Takagi K, Tochimoto A, Baba S, Okamoto Y, Ota Y, Yamanaka H: Clinical manifestations of neurological involvement in primary Sjögren’s syndrome. Clin Rheumatol. 2011, 30: 485-490. 10.1007/s10067-010-1458-7.View ArticlePubMed
- Kolfenbach JR, Horner BJ, Ferucci ED, West SG: Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis. Arthritis Care Res (Hoboken). 2011, 63: 1203-1208. 10.1002/acr.20486.View Article
- Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zéphir H, Moder K, Weinshenker BG: Neuromyelitis optica and non-organ specific autoimmunity. Arch Neurol. 2008, 65: 78-83. 10.1001/archneurol.2007.17.PubMed
- Jarius S, Jacobi C, de Seze J, Zephir H, Paul F, Franciotta D, Rommer P, Mader S, Kleiter I, Reindl M, Akman-Demir G, Seifert-Held T, Kristoferitsch W, Melms A, Wandinger KP, Wildemann B: Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler. 2011, 17: 1067-1073. 10.1177/1352458511403958.View ArticlePubMed
- Sánchez-Guerrero J, Pérez-Dosal MR, Celis-Aguilar E, Cárdenas-Velázquez F, Soto-Rojas AE, Avila-Casado C: Validity of screening tests for Sjögren’s syndrome in ambulatory patients with chronic diseases. J Rheumatol. 2006, 33: 907-911.PubMed
- Vitali C, Bombardieri S, Moutsopoulos HM: Preliminary criteria for the classification of Sjögren’s syndrome. Arthritis Rheum. 1993, 36: 340-347. 10.1002/art.1780360309.View ArticlePubMed
- Sanchez-Guerrero J, Aguirre-García E, Pérez-Dosal M, Kraus A, Cardiel MH, Soto-Rojas A: The wafer test: a semiquantitative test to screen for xerostomia. Rheumatology (Oxford). 2002, 41: 381-389. 10.1093/rheumatology/41.4.381.View Article
- Weinshenker BG, Wingerchuk DM: Neuromyelitis optica: Clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol. 2008, 318: 343-356. 10.1007/978-3-540-73677-6_14.PubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.